Spots Global Cancer Trial Database for glioblastoma
Every month we try and update this database with for glioblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | NCT04869449 | Glioblastoma Glioblastoma Mu... Glioblastoma Mu... Glioblastoma Mu... | Ketoconazole | 18 Years - | Milton S. Hershey Medical Center | |
| qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. | NCT02466828 | Glioblastoma Hypoxia | Feraheme® | 18 Years - | Sunnybrook Health Sciences Centre | |
| Chloroquine for Glioblastoma. | NCT04772846 | Glioblastoma | Oral tablet Placebo | 18 Years - 70 Years | Egyptian Medical Syndicate | |
| Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | NCT06279767 | Glioblastoma Cancer Temozolomide | 6-mercaptopurin... | 18 Years - 65 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | NCT00250211 | Glioblastoma Glioma | Functional MRI ... | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | NCT03643549 | Glioblastoma | Bortezomib and ... Bortezomib and ... | 18 Years - | Haukeland University Hospital | |
| Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors | NCT05383872 | Glioblastoma Glioma Liquid Biopsy | Focused Ultraso... | 18 Years - 80 Years | InSightec | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma | NCT00703859 | Glioblastoma | Dichloroacetate... | 18 Years - | AHS Cancer Control Alberta | |
| Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | NCT03980249 | Glioblastoma Glioblastoma Mu... | Carvedilol | 18 Years - | West Virginia University | |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma | NCT03278249 | Glioblastoma | Modified Atkins... | 18 Years - | University of Cincinnati | |
| Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer | NCT06385132 | Glioblastoma Head and Neck C... | Psychological T... | 18 Years - 75 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide | NCT04945148 | Glioblastoma, I... | Metformin Radiation IMRT Temozolomide | 18 Years - | Hopital Foch | |
| Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma | NCT04566185 | Glioblastoma | FDG PET CT scan Magnetic resona... | 18 Years - | Centre Hospitalier Universitaire de Nīmes | |
| Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue | NCT04545177 | Glioblastoma | NICO Myriad and... | 18 Years - | Case Comprehensive Cancer Center | |
| Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | NCT00200161 | Glioblastoma Gliomas | Temozolomide Temozolomide | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | NCT04324840 | Glioblastoma | CC-90010 Temozolomide Radiotherapy | 18 Years - | Celgene | |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | NCT05954858 | Glioma, Maligna... Glioblastoma Glioblastoma Mu... Glioblastoma Mu... High Grade Glio... GBM Brain Cancer | Tissue autograf... | 18 Years - | Northwell Health | |
| Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT02997423 | Glioblastoma | 21 Years - | University of Iowa | ||
| Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy | NCT03144167 | Glioblastoma Radiotherapy Chemotherapy | Analysis of spe... | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Disease Progression and Treatment-induced Alterations in Glioblastoma | NCT02152748 | Brain Tumor | analyze systema... | - | Medical University of Vienna | |
| Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion | NCT05990244 | Glioma | Magnetic Resona... Assessment and ... | 18 Years - 80 Years | Shengjing Hospital | |
| Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | NCT00302159 | High Grade Glio... Brain Tumors | adjuvant therap... Temozolomide Valproic Acid Radiation thera... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | NCT01269853 | Glioblastoma Mu... Anaplastic Astr... | Bevacizumab Bevacizumab | 18 Years - | Northwell Health | |
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | NCT03355794 | Diffuse Intrins... Malignant Gliom... High Grade Glio... Bithalamic High... Brainstem Gliom... Glioblastoma Anaplastic Astr... | ribociclib Everolimus | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | NCT01632228 | Glioblastoma | Bevacizumab Onartuzumab Placebo | 18 Years - | Hoffmann-La Roche | |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT00916409 | Glioblastoma Mu... | NovoTTF-100A de... Temozolomide | 18 Years - | NovoCure Ltd. | |
| Implantable Microdevice In Primary Brain Tumors | NCT04135807 | Grade II Glioma Grade III Gliom... Grade IV Glioma Astrocytoma Oligodendroglio... Anaplastic Astr... Anaplastic Olig... Glioblastoma | Microdevice | 18 Years - | Dana-Farber Cancer Institute | |
| Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma | NCT04657146 | Glioblastoma | Biorepository | 18 Years - | Duke University | |
| AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | NCT04881032 | Glioblastoma | Polysiloxane Gd... radiotherapy Temozolomide | 18 Years - 75 Years | Centre Jean Perrin | |
| Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | NCT05831995 | Advanced Solid ... RAS Mutation RAF Mutation NF1 Mutation | ABM-168 | 18 Years - | ABM Therapeutics Corporation | |
| A Panobinostat Presurgery | NCT01115036 | Recurrent Gliob... | panobinostat | 18 Years - | Duke University | |
| Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | NCT02039778 | Glioblastoma Malignant Gliom... Brain Tumors Anaplastic Astr... | Stem Cell Radio... | 18 Years - 70 Years | Beth Israel Medical Center | |
| Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma | NCT03439332 | Glioblastoma | 18 Years - | Universitat Politècnica de València | ||
| CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | NCT04933422 | Glioblastoma | CM93 | 18 Years - | Crimson Biopharm Inc. | |
| Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | NCT06132438 | Glioblastoma | PEP-CMV vaccine | 18 Years - 100 Years | The University of New South Wales | |
| Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | NCT02833701 | Glioblastoma Glioma | Ascorbic Acid Bevacizumab Laboratory Biom... Quality-of-Life... | 19 Years - | University of Nebraska | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | NCT03451799 | GBM Glioblastoma | Ketogenic Diet Standard-of-car... Standard-of-car... | 18 Years - | Cedars-Sinai Medical Center | |
| Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults | NCT01043536 | Glioblastoma | radiotherapy temozolomide | 18 Years - 70 Years | Centre Georges Francois Leclerc | |
| Establishment of a Signature of Circulating microRNA as a Tool to Aid Diagnosis of Primary Brain Tumors in Adults | NCT03630861 | Brain Tumors | 50 Years - 75 Years | Assistance Publique - Hôpitaux de Paris | ||
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | NCT03927222 | Glioblastoma | Human CMV pp65-... Temozolomide Tetanus-Diphthe... GM-CSF 111-Indium-labe... | 18 Years - | Duke University | |
| NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | NCT01954576 | Glioblastoma Brain Neoplasms | NovoTTF-100A Quality-of-life... Laboratory biom... | 22 Years - | University of Florida | |
| 5-ALA in Recurrent Glioma | NCT02119338 | Glioma | 5-ala | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | NCT04323046 | Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Malig... Recurrent Grade... Grade III Gliom... | Nivolumab Quality-of-Life... Questionnaire A... | 6 Months - 25 Years | University of California, San Francisco | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Targeted Pediatric High-Grade Glioma Therapy | NCT05839379 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | 12 Months - 39 Years | Nationwide Children's Hospital | ||
| The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma | NCT02189109 | Glioblastoma Mu... | NVX-108 | 18 Years - 70 Years | NuvOx LLC | |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | NCT03197506 | Glioblastoma Gliosarcoma Supratentorial ... | External Beam R... Laboratory Biom... Pembrolizumab Radiation Thera... Temozolomide Therapeutic Con... | 18 Years - | Mayo Clinic | |
| 18F-FluorThanatrace (PET/CT) in Glioblastoma | NCT04221061 | Glioblastoma | 18F-FluorThanat... | 22 Years - | University of Pennsylvania | |
| Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | NCT03347617 | Glioblastoma | Ferumoxytol Laboratory Biom... Magnetic Resona... Pembrolizumab | 18 Years - | OHSU Knight Cancer Institute | |
| RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | NCT04963413 | Glioblastoma | Autologous DCs ... | 18 Years - 90 Years | University of Florida | |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | NCT03707457 | Glioblastoma Glioblastoma Mu... | Nivolumab Anti-GITR Monoc... IDO1 inhibitor ... Ipilimumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma | NCT04900792 | Glioblastoma Glioblastoma Mu... | Ferumoxytol inj... Pharmacological... External beam r... Temozolomide | 18 Years - | University of Iowa | |
| Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma | NCT06222138 | Glioblastoma | The samples des... | 18 Years - | Institut Claudius Regaud | |
| Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence | NCT04846257 | Glioblastoma | Dynamic contras... | - | Egyptian Medical Syndicate | |
| An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) | NCT01598597 | Breast Cancer Colorectal Canc... Non-Small Cell ... Glioblastoma Renal Cell Canc... | 18 Years - | Genentech, Inc. | ||
| CART-EGFRvIII + Pembrolizumab in GBM | NCT03726515 | Glioblastoma | CART-EGFRvIII T... Pembrolizumab | 18 Years - | University of Pennsylvania | |
| Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) | NCT00797940 | Glioblastoma Mu... | IL-4PE | 18 Years - | Protox Inc. | |
| ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma | NCT03322813 | Glioma | ExAblate 4000 -... | 21 Years - 85 Years | InSightec | |
| Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | NCT01898273 | Glioblastoma | I-124-CLR1404 | 18 Years - | Cellectar Biosciences, Inc. | |
| Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma | NCT02067156 | Glioblastoma Mu... | G-202 | 18 Years - | GenSpera, Inc. | |
| Bevacizumab With or Without Surgery for Adult Glioblastomas | NCT01413438 | Glioblastoma Brain Neoplasm | Craniotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | NCT03330197 | Pediatric Brain... Diffuse Intrins... | Ad-RTS-hIL-12 Oral Veledimex ... Oral Veledimex ... | 0 Years - 21 Years | Alaunos Therapeutics | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | NCT05241392 | Glioblastoma | B7-H3-targeting... | 18 Years - 75 Years | Beijing Tiantan Hospital | |
| Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | NCT01310868 | Glioblastoma | 5-ALA Gliadel wafers Radiotherapy as... Concomitant che... Adjuvant chemot... | 18 Years - | University College, London | |
| Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma | NCT02799238 | Glioblastoma | ALECSAT Radiotherapy Temozolomide | 18 Years - 70 Years | CytoVac A/S | |
| Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | NCT02858895 | Glioblastoma Grade IV Astroc... Glioblastoma Mu... Grade IV Glioma | MDNA55 | 18 Years - | Medicenna Therapeutics, Inc. | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) | NCT06147505 | Glioblastoma GBM | XS005 Cell Inje... Temozolomide（TM... | 18 Years - 70 Years | Dushu Lake Hospital Affiliated to Soochow University | |
| Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas. | NCT03115138 | Glioblastoma Molecular Disea... | Correlation bet... | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma | NCT00694837 | Glioblastoma | nelfinavir | 18 Years - 65 Years | Maastricht Radiation Oncology | |
| MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma | NCT04596930 | Glioblastoma | Laser ablation ... | 18 Years - | Radboud University Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
